Compugen USA, Inc.

9 articles about Compugen USA, Inc.

• Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

  2/14/2023

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported today that rilvegostomig, AstraZeneca's bi-specific antibody derived from Compugen's COM902, is expected to progress into Phase 3 this year.

• Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

  2/13/2023

  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023, before the U.S. financial markets open. 

• Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

  11/6/2019

  Added to previously granted U.S. patent protecting the use of COM902 for T cell activation in cancer patients

• Compugen Announces FDA Clearance of IND Application for COM902

  11/4/2019

  Clinical development of COM902 will enable testing the combination treatment with COM701, Compugen's anti-PVRIG inhibitor

• 

  AACR Meeting Brief: Compugen, Bayer, Tarveda, Alligator and Others

  4/17/2018

  Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.

• Dr. Elliott Sigal Joins Compugen Ltd. As Strategic Advisor And Prof. Drew Pardoll Appointed Director At Compugen USA, Inc.

  4/6/2016

• Compugen Ltd. Presents Experimental Results Supporting Induction of Immune Tolerance by CGEN-15001 Drug Candidate

  10/16/2013

• Compugen Ltd. Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

  4/17/2013

• Genzyme Beats Expectations, Jumps 12%

  7/15/2004